Drug prescription patterns in patients with Addison's disease: A Swedish population-based cohort study

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 5, 2013, Pages 2009-2018

  Björnsdottir, Sigridur ^a   Sundström, Anders ^a   Ludvigsson, Jonas F ^a,b   Blomqvist, Paul ^a   Kämpe, Olle ^c   Bensing, Sophie ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ANTIANEMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CORTISONE ACETATE; CYANOCOBALAMIN; DIURETIC AGENT; ESTROGEN; FLUDROCORTISONE; FOLIC ACID; GASTROINTESTINAL AGENT; HYDROCORTISONE; HYPNOTIC AGENT; INSULIN; LAXATIVE; MACROLIDE; NOOTROPIC AGENT; POTASSIUM; PROGESTERONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEDATIVE AGENT; TETRACYCLINE; UNINDEXED DRUG;

ADDISON DISEASE; ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE REGISTRY; ETHNICITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; SWEDEN; SWEDISH;

ADDISON DISEASE; ADRENAL CORTEX HORMONES; ADULT; ANTIHYPERTENSIVE AGENTS; AUTOIMMUNE DISEASES; COHORT STUDIES; DIURETICS; DRUG PRESCRIPTIONS; FEMALE; GASTROINTESTINAL AGENTS; HEMATINICS; HORMONE REPLACEMENT THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; REGISTRIES; SWEDEN;

EID: 84877710970     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3561     Document Type: Article

References (41)

1. Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. Postgrad Med J. 1997;73:286-288.
2. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004;350:2068-2079.
3. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002;23:327-364.
4. Takayanagi R, Miura K, Nakagawa H, Nawata H. Epidemiologic study of adrenal gland disorders in Japan. Biomed Pharmacother. 2000;54(Suppl 1):164s-168s
5. Bleicken B, Hahner S, Ventz M, Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci. 2010;339:525-531.
6. Lövas K, Husebye ES. Replacement therapy for Addison's disease: recent developments. Expert Opin Investig Drugs. 2008;17:497- 509.
7. Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab. 2007; 92:3912-3922.
8. Lövas K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf). 2002; 56:581-588.
9. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab. 2006;91:4849-4853.
10. Bensing S, Brandt L, Tabaroj F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf). 2008;69:697-704.
11. Reisch N, Arlt W. Fine tuning for quality of life: 21st century approach to treatment of Addison's disease. Endocrinol Metab Clin North Am. 2009;38:407-418, ix-x
12. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
13. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register: opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726-735.
14. WHO Collaborating Centre for Drug Statistics and Methodology ATC/DDD Index 2013. http://www.whocc.no/atc-ddd-index/. Updated December 20, 2012.
15. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659- 667.
16. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol II. The Design and Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer; 1987.
17. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.
18. Erichsen MM, Lövas K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009;94:4882-4890.
19. Valenzuela GA, Smalley WE, Schain DC, Vance ML, McCallum RW. Reversibility of gastric dysmotility in cortisol deficiency. Am J Gastroenterol. 1987;82:1066-1068.
20. 12). Ann Intern Med. 1994;120:211-215.
21. Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf). 1997;46:255-261.
22. Crown A, Lightman S. Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf). 2005;63:483-492.
23. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. National Institutes of Health. Obes Res. 1998;6(Suppl 2):51S-209S.
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106: 3143-3421.
25. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341:1013-1020.
26. Gurnell EM, Hunt PJ, Curran SE, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab. 2008;93:400-409.
27. Becker C. Hypothyroidism and atherosclerotic heart disease: pathogenesis, medical management, and the role of coronary artery bypass surgery. Endocr Rev. 1985;6:432-440.
28. Giordano R, Marzotti S, Balbo M, et al. Metabolic and cardiovas cular profile in patients with Addison's disease under conventional glucocorticoid replacement. J Endocrinol Invest. 2009;32:917-923.
29. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2011;
30. Alimohammadi M, Dubois N, Sköldberg F, et al. Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen. Proc Natl Acad Sci USA. 2009;106:4396-4401.
31. Ludvigsson JF, Inghammar M, Ekberg M, Egesten A. A nationwide cohort study of the risk of chronic obstructive pulmonary disease in coeliac disease. J Intern Med. 2011;
32. Lövas K, Husebye ES, Holsten F, Bjorvatn B. Sleep disturbances in patients with Addison's disease. Eur J Endocrinol. 2003;148:449- 456.
33. Garcia-Borreguero D, Wehr TA, Larrosa O, et al. Glucocorticoid replacement is permissive for rapid eye movement sleep and sleep consolidation in patients with adrenal insufficiency. J Clin Endocrinol Metab. 2000;85:4201-4206.
34. Lövas K, Gjesdal CG, Christensen M, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol. 2009;160:993-1002.
35. Björnsdottir S, Sääf M, Bensing S, Kämpe O, Michaelsson K, Ludvigsson JF. Risk of hip fracture in Addison's disease: a populationbased cohort study. J Intern Med. 2011;270:187-195.
36. Li Voon Chong JS, Sen J, Johnson Z, Kyle G, MacFarlane IA. Hydrocortisone replacement dosage influences intraocular pressure in patients with primary and secondary hypocortisolism. Clin Endocrinol (Oxf). 2001;54:267-271.
37. Björnsdottir S, Cnattingius S, Brandt L, et al. Addison's disease in women is a risk factor for an adverse pregnancy outcome. J Clin Endocrinol Metab. 2010;95:5249-5257.
38. Erichsen MM, Husebye ES, Michelsen TM, Dahl AA, Lövas K. Sexuality and fertility in women with Addison's disease. J Clin Endocrinol Metab. 2010;95:4354-4360.
39. Dahlquist G, Mustonen L. Analysis of 20 years of prospective registration of childhood onset diabetes time trends and birth cohort effects. Swedish Childhood Diabetes Study Group. Acta Paediatr. 2000;89:1231-1237.
40. Ahlgren C, Oden A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler. 2011;17:901-908.
41. Söderbergh A, Winqvist O, Norheim I, et al. Adrenal autoantibodies and organ-specific autoimmunity in patients with Addison's disease. Clin Endocrinol (Oxf). 1996;45:453-460.